Permeon Biologics
 | |
| private | |
| Industry |
Health care Biotechnology |
| Founded | 2011 |
| Founder | David R. Liu |
| Headquarters | Cambridge, Massachusetts, United States |
Key people |
John Ripple Noubar Afeyan |
| Products | Intraphilin™ Technology Platform |
| Website | permeonbio.com |
Permeon Biologics, Inc. is a privately held pharmaceutical and biotechnology company in Cambridge, Massachusetts. Founded in 2011 by Harvard chemist David R. Liu and Noubar Afeyan, CEO of Flagship Ventures, the company’s develops a class of proteins, under the trademark Intraphilin™, that enable the transport of large molecules such as antibodies into cells, thereby potentially enabling new classes of intracellular therapies.[1][2]
Ownership
Permeon Biologics closed a Series A financing in November, 2010, with Flagship Ventures of Cambridge, Massachusetts, and ARCH Venture Partners of Chicago.[3]
References
- ↑ Brian Gormley, "Flagship Ventures Hatches Two More Health-Care Companies", The Wall Street Journal (March 17, 2011)
- ↑ James J. Cronican, Kevin T. Beier, Tina N. Davis, Jen-Chieh Tseng, Weida Li, David B. Thompson, Allen F. Shih, Erin M. May, Constance L. Cepko, Andrew L. Kung, Qiao Zhou, and David R. Liu "A Class of Human Proteins That Deliver Functional Proteins Into Mammalian Cells In Vitro and In Vivo", Chem Biol, 2011 July 29, 18(7), 833–838
- ↑ Permeon Biologics, "Investors"
This article is issued from Wikipedia - version of the 11/16/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.